Epigenetic silencing of UBXN8 contributes to leukemogenesis in t(8;21) acute myeloid leukemia
3
조회
0
다운로드
0
인용
0
참고문헌
초록
The formation of the RUNX1-RUNX1T1 fusion protein, resulting from the t(8;21) translocation, is considered to be one of the initiating events of t(8;21) acute myeloid leukemia (AML). However, the mechanisms of the oncogenic mechanism of RUNX1-RUNX1T1 remain unclear. In this study, we found that RUNX1-RUNX1T1 triggers the heterochromatic silencing of UBXN8 by recognizing the RUNX1-binding sites and recruiting chromatin-remodeling enzymes to the UBXN8 promoter region. Decitabine, a specific inhibitor of DNA methylation, upregulated the expression of UBXN8 in RUNX1-RUNX1T1 + AML cell lines. Overexpression of UBXN8 inhibited the proliferation and colony-forming ability of and promoted cell cycle arrest in t(8;21) AML cell lines. Enhancing UBXN8 levels can significantly inhibit tumor proliferation and promote the differentiation of RUNX1-RUNX1T1 + cells in vivo. In conclusion, our results indicated that epigenetic silencing of UBXN8 via methylation of its promoter region mediated by the RUNX1-RUNX1T1 fusion protein contributes to the leukemogenesis of t(8;21) AML and that UBXN8 targeting may be a potential therapeutic strategy for t(8;21) AML.
Abstract
The formation of the RUNX1-RUNX1T1 fusion protein, resulting from the t(8;21) translocation, is considered to be one of the initiating events of t(8;21) acute myeloid leukemia (AML). However, the mechanisms of the oncogenic mechanism of RUNX1- RUNX1T1 remain unclear. In this study, we found that RUNX1-RUNX1T1 triggers the heterochromatic silencing of UBXN8 by recognizing the RUNX1-binding sites and recruiting chromatin-remodeling enzymes to the UBXN8 promoter region. Decitabine, a specific inhibitor of DNA methylation, upregulated the expression of UBXN8 in RUNX1-RUNX1T1+ AML cell lines. Overexpression of UBXN8 inhibited the proliferation and colony-forming ability of and promoted cell cycle arrest in t(8;21) AML cell lines. Enhancing UBXN8 levels can significantly inhibit tumor proliferation and promote the differentiation of RUNX1-RUNX1T1+ cells in vivo. In conclusion, our results indicated that epigenetic silencing of UBXN8 via methylation of its promoter region mediated by the RUNX1- RUNX1T1 fusion protein contributes to the leukemogenesis of t(8;21) AML and that UBXN8 targeting may be a potential therapeutic strategy for t(8;21) AML.
참고문헌 (25)
- Martinez-Soria, N., "The oncogenic transcription factor RUNX1", ETO corrupts cell cycle regulation to drive leukemic transformation, 2018, pp.34, ~
- Liu, S., "RUNX1 inhibits proliferation and induces apoptosis of t(8;21)leukemia cells via KLF4-mediated transactivation of P57", Haematologica, 104, pp.1597~1607 (2019)
- Li, Y., "Clinical implications of genome-wide DNA methylation studies in acute myeloid leukemia", J. Hematol. Oncol, 10, pp.41~ (2017)
- Li, Y., "A novel epigenetic AML1-ETO", THAP10, Embo. Mol. Med, pp.2017, 9[DOI]
- Rezvani, K., "UBXD proteins : a family of proteins with diverse functions in cancer", Int. J. Mol. Sci, 17, pp.1724~ (2016)
- Madsen, L., "The tissue-specific Rep8", UBXD6 tethers p97 to the endoplasmic reticulum membrane for degradation of misfolded proteins, 2011, pp.6, e25061~
- Maccalli, C., "Identification of a colorectal tumor-associated antigen(COA-1)recognized by CD4(+)T lymphocytes", Cancer Res, 63, pp.6735~6743 (2003)
- Sane, S., "Ubiquitin-like(UBX)-domain-containing protein, UBXN2A, promotes cell death by interfering with the p53-Mortalin interactions in colon cancer cells", Cell Death Dis, 5, pp.e1118~ (2014)
- Sane, S., "UBXN2A enhances CHIP-mediated proteasomal degradation of oncoprotein mortalin-2 in cancer cells", Mol. Oncol, 12, pp.1753~1777 (2018)
- Li, X., "The function of targeted host genes determines the oncogenicity of HBV integration in hepatocellular carcinoma", J. Hepatol, 60, pp.975~984 (2014)
- Allum, F., "Characterization of functional methylomes by next-generation capture sequencing identifies novel disease-associated variants", Nat. Commun, 6, pp.7211~ (2015)
- Fazi, F., "Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1", ETO oncoprotein, 2007, pp.12, 457~466
- Martinez Soria, N., "Transient depletion of RUNX1", RUNX1T1 by RNA interference delays tumour formation in vivo, 2009, pp.23, 188~190
- Li, Y., "Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21)acute myeloid leukemia by activating the PTEN", PI3K signal pathway, 2013, pp.121, 499~509
- Livak, K. J., "Analysis of relative gene expression data using realtime quantitative PCR and the 2(-Delta Delta C(T))Method", Methods, 25, pp.402~408 (2001)
- Xi, Y., "BSMAP : whole genome bisulfite sequence MAPping program", Bmc Bioinforma, 10, pp.232~ (2009)
- Jühling, F., "metilene : fast and sensitive calling of differentially methylated regions from bisulfite sequencing data", Genome Res, 26, pp.256~262 (2016)
- Mino-Kenudson, M., "Immunohistochemistry for predictive biomarkers in nonsmall cell lung cancer", Transl. Lung. Cancer Res, 6, pp.570~587 (2017)
- Gao, X. N., "AML1", ETO cooperates with HIF1alpha to promote leukemogenesis through DNMT3a transactivation, 2015, pp.29, 1730~1740
- Lei Zhou, "Methylation-associated silencing of BASP1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia", Experimental and Molecular Medicine, 50, pp.1~8 (2018), 생화학분자생물학회
- Figueroa, M. E., "Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation", Cancer Cell, 18, pp.553~567 (2010)
- Sun, Z., "Guardians of the ERAD Galaxy", Cell, 171, pp.267~268 (2017)
- Ballar, P., "Regulation of ER-associated degradation via p97", VCP-interacting motif, 2008, pp.36, 818~822
- Guerriero, C. J., "The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology", Physiol. Rev, 92, pp.537~576 (2012)
- Jeon, Y. J., "miRNA-mediated TUSC3 deficiency enhances UPR and ERAD to promote metastatic potential of NSCLC", Nat. Commun, 9, pp.5110~ (2018)